Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
J Clin Med ; 11(6)2022 Mar 17.
Article in English | MEDLINE | ID: mdl-35329991

ABSTRACT

BACKGROUND: This prospective observational study aimed to verify the efficacy of erythropoietin zeta in the treatment of patients with low-risk myelodysplastic syndrome. METHODS: Patients with low/int-1 IPSS risk and serum erythropoietin level below 500 U/L were enrolled. Treatment consisted of erythropoietin zeta 40,000 U subcutaneously once a week. The primary endpoint was the erythroid response. According to Simon's two-stage statistical design, 36 patients were recruited. The median age was 75 years (range 56-83 years), male/female ratio was 1.1/1, median baseline serum erythropoietin was 57.9 U/L (range 9.4-475 U/L). 53% of patients had low-risk disease, while the remaining had Int-1 risk. RESULTS: After 8 weeks, a significant response (rise in Hb levels of at least 1.5 g/dL) was achieved in 18 patients (50%) out of 36. However, 17 patients did not improve; 8/17 patients pursued the 40,000 U weekly schedule of erythropoietin zeta, and 4/8 (50%) of them reached the erythroid response after 16 weeks. Nine patients underwent dosage doubling (40,000 U twice per week), and 5/9 (55%) of them achieved the erythroid response. CONCLUSION: Compared with data from the literature, this prospective study revealed that EPO-zeta is a safe and effective therapeutic option in low-risk MDS patients.

2.
Leuk Res ; 38(1): 57-64, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24238640

ABSTRACT

The revised IPSS (IPSS-R) was developed aiming at a better prognostication, taking into account patients treated with best supportive care. We herein validated this model on the basis of data from 1314 patients who received BSC only as well as patients who underwent induction chemotherapy (n=214) or allogeneic transplantation (n=167). We could demonstrate a clear distinction of the IPSS-R risk categories with regard to survival and risk of AML evolution in all patient cohorts. When comparing IPSS-R, IPSS, WHO prognostic scoring system (WPSS) and Duesseldorf score, the best results regarding the ability to predict survival were obtained by the IPSS-R.


Subject(s)
Leukemia, Myeloid/therapy , Myelodysplastic Syndromes/therapy , Risk Assessment/methods , Acute Disease , Adolescent , Adult , Aged , Aged, 80 and over , Disease Progression , Female , Humans , Leukemia, Myeloid/pathology , Male , Middle Aged , Multivariate Analysis , Myelodysplastic Syndromes/pathology , Prognosis , Reproducibility of Results , Risk Factors , Survival Analysis , Young Adult
3.
Haematologica ; 97(1): 82-8, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21933849

ABSTRACT

BACKGROUND: Bernard-Soulier syndrome is a very rare form of inherited thrombocytopenia that derives from mutations in GPIbα, GPIbß, or GPIX and is typically inherited as a recessive disease. However, some years ago it was shown that the monoallelic c.515C>T transition in the GPIBA gene (Bolzano mutation) was responsible for macrothrombocytopenia in a few Italian patients. DESIGN AND METHODS: Over the past 10 years, we have searched for the Bolzano mutation in all subjects referred to our institutions because of an autosomal, dominant form of thrombocytopenia of unknown origin. RESULTS: We identified 42 new Italian families (103 cases) with a thrombocytopenia induced by monoallelic Bolzano mutation. Analyses of the geographic origin of affected pedigrees and haplotypes indicated that this mutation originated in southern Italy. Although the clinical expression was variable, patients with this mutation typically had a mild form of Bernard-Soulier syndrome with mild thrombocytopenia and bleeding tendency. The most indicative laboratory findings were enlarged platelets and reduced GPIb/IX/V platelet expression; in vitro platelet aggregation was normal in nearly all of the cases. CONCLUSIONS: Our study indicates that monoallelic Bolzano mutation is the most frequent cause of inherited thrombocytopenia in Italy, affecting 20% of patients recruited at our institutions during the last 10 years. Because many people from southern Italy have emigrated during the last century, this mutation may have spread to other countries.


Subject(s)
Bernard-Soulier Syndrome/genetics , Heterozygote , Membrane Glycoproteins/genetics , Mutation, Missense , Thrombocytopenia/diagnosis , Thrombocytopenia/genetics , Adolescent , Adult , Aged , Aged, 80 and over , Bernard-Soulier Syndrome/diagnosis , Child , Child, Preschool , Family Health , Female , Humans , Infant , Italy , Male , Middle Aged , Platelet Aggregation , Platelet Count , Platelet Glycoprotein GPIb-IX Complex , Polymorphism, Genetic , Thrombocytopenia/therapy , Thrombopoietin/blood , Tubulin/genetics , Young Adult
5.
Haematologica ; 96(3): 417-23, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21173099

ABSTRACT

BACKGROUND: Bernard-Soulier syndrome is a severe bleeding disease due to a defect of GPIb/IX/V, a platelet complex that binds the von Willebrand factor. Due to the rarity of the disease, there are reports only on a few cases compromising any attempt to establish correlations between genotype and phenotype. In order to identify any associations, we describe the largest case series ever reported, which was evaluated systematically at the same center. DESIGN AND METHODS: Thirteen patients with the disease and seven obligate carriers were enrolled. We collected clinical aspects and determined platelet features, including number and size, expression of membrane glycoproteins, and ristocetin induced platelet aggregation. Mutations were identified by direct sequencing of the GP1BA, GP1BB, and GP9 genes and their effect was shown by molecular modeling analyses. RESULTS: Patients all had a moderate thrombocytopenia with giant platelets and a bleeding tendency whose severity varied among individuals. Consistent with expression levels of GPIbα always lower than 10% of control values, platelet aggregation was absent or severely reduced. Homozygous mutations were identified in the GP1BA, GP1BB and GP9 genes; six were novel alterations expected to destabilize the conformation of the respective protein. Except for obligate carriers of a GP9 mutation with a reduced GPIb/IX/V expression and defective aggregation, all the other carriers had no obvious anomalies. CONCLUSIONS: Regardless of mutations identified, the patients' bleeding diathesis did not correlate with thrombocytopenia, which was always moderate, and platelet GPIbα expression, which was always severely impaired. Obligate carriers had features similar to controls though their GPIb/IX/V expression showed discrepancies. Aware of the limitations of our cohort, we cannot define any correlations. However, further investigations should be encouraged to better understand the causes of this rare and underestimated disease.


Subject(s)
Bernard-Soulier Syndrome/physiopathology , Membrane Glycoproteins/analysis , Platelet Glycoprotein GPIb-IX Complex/metabolism , Adolescent , Adult , Amino Acid Sequence , Bernard-Soulier Syndrome/blood , Bernard-Soulier Syndrome/genetics , Blood Platelets/pathology , Cell Shape , Child , Child, Preschool , Female , Genetic Association Studies , Genetic Markers , Hemorrhage , Homozygote , Humans , Italy , Male , Membrane Glycoproteins/genetics , Middle Aged , Molecular Sequence Data , Platelet Aggregation/drug effects , Platelet Count , Platelet Glycoprotein GPIb-IX Complex/genetics , Point Mutation , Polymerase Chain Reaction , Ristocetin/pharmacology , Thrombocytopenia/blood , Young Adult , von Willebrand Factor/metabolism
7.
Haematologica ; 88(4): 429-37, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12681970

ABSTRACT

BACKGROUND AND OBJECTIVES: Loss of heterozygosity (LOH) on the long arm of chromosome 7 (7q) has been frequently reported in several types of human cancer including hematologic malignancies. Moreover, monosomy of chromosome 7 and 7q deletions have been associated in acute myeloid leukemia (AML) with aggressive disease and poor prognosis. DESIGN AND METHODS: Using a panel of 11 polymorphic microsatellite markers at bands 7q21-q36, we investigated fifty patients (acute myeloid leukemia [AML], n=33 and acute lymphoid leukemia [ALL], n=17) for LOH, a hallmark of possible involvement of tumor suppressor genes. In parallel, the same acute leukemia (AL) cases were studied by conventional cytogenetics. RESULTS: A total of 48 spots of allelic loss were observed in 16 (32%) out of 50 patients (AML, n=11 and ALL, n=5). Among LOH+ve cases 3 showed chromosome 7 monosomies, whereas no cytogenetically detectable abnormalities were observed in chromosome 7 in the remaining 13. INTERPRETATION AND CONCLUSIONS: Comparison with karyotypic results indicated that presence of LOH at 7q21-q36 was significantly associated with other chromosomal aberrations. In fact, an altered karyotype was detectable in 87% of LOH+ve and in 52% of LOH(-ve) AL cases (p=0.024). In addition, LOH at 7q was prevalently associated with unfavorable cytogenetic lesions (p=0.013). Our study represents the first report of a significant association between LOH and recurrent chromosomal abnormalities in AL patients suggesting that the 7q21-q36, region may be an unstable area prone to chromosome breakage in patients with an abnormal karyotype.


Subject(s)
Chromosome Aberrations , Chromosomes, Human, Pair 7 , Leukemia/genetics , Sequence Deletion , Acute Disease , Adolescent , Adult , Aged , Child , Cytogenetic Analysis , Female , Humans , Loss of Heterozygosity/genetics , Male , Middle Aged , Recurrence
8.
Cancer Genet Cytogenet ; 140(1): 13-7, 2003 Jan 01.
Article in English | MEDLINE | ID: mdl-12550752

ABSTRACT

A new t(20;21)(q11;q11), associated with a deletion on the long arm of chromosome 20, was found in one patient with an acute myelocytic leukemia (AML) and in one with myelodysplastic syndrome (MDS). In both cases deletion was interstitial, extending from band q11 to band q13, as shown by comparative genomic hybridization (CGH) and fluorescence in situ hybridization (FISH). FISH analysis with whole arm paints, subtelomeric probes, and locus-specific probes for the long arms of chromosomes 20 and 21 revealed in patient 1 a reciprocal translocation between the deleted 20q and the long arm of chromosome 21, that is, del(20)(q11q13)t(20;21)(q11;q11), and in patient 2, material from 21q was inserted into the deleted 20q, that is, del(20)(q11q13)ins(20;21)(q11;q11q22). This is the first identification of a complex 20;21 rearrangement in MDS/AML. Deletion at 20q and juxtaposition between 20q11 and 21q11 appear to be the critical genomic events.


Subject(s)
Anemia, Refractory, with Excess of Blasts/genetics , Chromosomes, Human, Pair 20/genetics , Chromosomes, Human, Pair 21/genetics , Leukemia, Myeloid, Acute/genetics , Translocation, Genetic , Aged , Chromosome Banding , Chromosome Breakage , Chromosome Deletion , Fatal Outcome , Female , Humans , In Situ Hybridization, Fluorescence , Karyotyping , Male , Middle Aged , Nucleic Acid Hybridization
SELECTION OF CITATIONS
SEARCH DETAIL
...